PDBsum entry 2a4l

Go to PDB code: 
protein ligands links
Transferase PDB id
Protein chain
286 a.a. *
Waters ×82
* Residue conservation analysis
PDB id:
Name: Transferase
Title: Human cyclin-dependent kinase 2 in complex with roscovitine
Structure: Homo sapiens cyclin-dependent kinase 2. Chain: a. Synonym: cdk2. Engineered: yes
Source: Homo sapiens. Human. Organism_taxid: 9606. Expressed in: spodoptera frugiperda. Expression_system_taxid: 7108. Expression_system_cell_line: sf9 cells.
2.40Å     R-factor:   0.173     R-free:   0.270
Authors: W.F.De Azevedo Jr.,S.H.Kim
Key ref: W.F.De Azevedo et al. (1997). Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem, 243, 518-526. PubMed id: 9030780
29-Jun-05     Release date:   03-Oct-06    
Go to PROCHECK summary

Protein chain
Pfam   ArchSchema ?
P24941  (CDK2_HUMAN) -  Cyclin-dependent kinase 2
298 a.a.
286 a.a.
Key:    PfamA domain  Secondary structure  CATH domain

 Enzyme reactions 
   Enzyme class: E.C.  - Cyclin-dependent kinase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: ATP + a protein = ADP + a phosphoprotein
+ protein
+ phosphoprotein
Molecule diagrams generated from .mol files obtained from the KEGG ftp site
 Gene Ontology (GO) functional annotation 
  GO annot!
  Cellular component     cyclin-dependent protein kinase holoenzyme complex   14 terms 
  Biological process     regulation of gene silencing   27 terms 
  Biochemical function     nucleotide binding     12 terms  


Eur J Biochem 243:518-526 (1997)
PubMed id: 9030780  
Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine.
W.F.De Azevedo, S.Leclerc, L.Meijer, L.Havlicek, M.Strnad, S.H.Kim.
Cyclin-dependent kinases (cdk) control the cell division cycle (cdc). These kinases and their regulators are frequently deregulated in human tumours. A potent inhibitor of cdks, roscovitine [2-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurin e], was identified by screening a series of C2,N6,N9-substituted adenines on purified cdc2/cyclin B. Roscovitine displays high efficiency and high selectivity (Meijer, L., Borgne, A., Mulner, O., Chong, J. P. J., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J.-G. & Moulinoux, J.-P. (1997) Eur. J. Biochem. 243, 527-536). It behaves as a competitive inhibitor for ATP binding to cdc2. We determined the crystal structure of a complex between cdk2 and roscovitine at 0.24-nm (2.4 A) resolution and refined to an Rfactor of 0.18. The purine portion of the inhibitor binds to the adenine binding pocket of cdk2. The position of the benzyl ring group of the inhibitor enables the inhibitor to make contacts with the enzyme not observed in the ATP-complex structure. Analysis of the position of this benzyl ring explains the specificity of roscovitine in inhibiting cdk2. The structure also reveals that the (R)-stereoisomer of roscovitine is bound to cdk2. The (R)-isomer is about twice as potent in inhibiting cdc2/cyclin B than the (S)-isomer. Results from structure/activity studies and from analysis of the cdk2/roscovitine complex crystal structure should allow the design of even more potent cdk inhibitors.

Literature references that cite this PDB file's key reference

  PubMed id Reference
21328450 J.Węsierska-Gądek, D.Gritsch, N.Zulehner, O.Komina, and M.Maurer (2011).
Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells.
  J Cell Biochem, 112, 761-772.  
21308739 J.Węsierska-Gądek, D.Gritsch, N.Zulehner, O.Komina, and M.Maurer (2011).
Interference with ER-α enhances the therapeutic efficacy of the selective CDK inhibitor roscovitine towards ER-positive breast cancer cells.
  J Cell Biochem, 112, 1103-1117.  
20836132 J.Węsierska-Gądek, M.Maurer, N.Zulehner, and O.Komina (2011).
Whether to target single or multiple CDKs for therapy? That is the question.
  J Cell Physiol, 226, 341-349.  
21080333 J.Węsierska-Gądek, S.Hackl, N.Zulehner, M.Maurer, and O.Komina (2011).
Reconstitution of human MCF-7 breast cancer cells with caspase-3 does not sensitize them to action of CDK inhibitors.
  J Cell Biochem, 112, 273-288.  
21286784 P.Dobeš, J.Fanfrlík, J.Rezáč, M.Otyepka, and P.Hobza (2011).
Transferable scoring function based on semiempirical quantum mechanical PM6-DH2 method: CDK2 with 15 structurally diverse inhibitors.
  J Comput Aided Mol Des, 25, 223-235.  
21253554 R.Conyers, S.Young, and D.M.Thomas (2011).
Liposarcoma: molecular genetics and therapeutics.
  Sarcoma, 2011, 483154.  
21087997 V.Quennet, A.Beucher, O.Barton, S.Takeda, and M.Löbrich (2011).
CtIP and MRN promote non-homologous end-joining of etoposide-induced DNA double-strand breaks in G1.
  Nucleic Acids Res, 39, 2144-2152.  
20013135 B.Zhang, Z.C.Su, T.E.Tay, and V.B.Tan (2010).
Mechanism of CDK5 activation revealed by steered molecular dynamics simulations and energy calculations.
  J Mol Model, 16, 1159-1168.  
20448906 C.Wong, R.J.Griffin, I.R.Hardcastle, J.S.Northen, L.Z.Wang, and B.T.Golding (2010).
Synthesis of sulfonamide-based kinase inhibitors from sulfonates by exploiting the abrogated SN2 reactivity of 2,2,2-trifluoroethoxysulfonates.
  Org Biomol Chem, 8, 2457-2464.  
20450234 C.X.Gong, I.Grundke-Iqbal, and K.Iqbal (2010).
Targeting tau protein in Alzheimer's disease.
  Drugs Aging, 27, 351-365.  
20028770 F.Galimberti, S.L.Thompson, X.Liu, H.Li, V.Memoli, S.R.Green, J.DiRenzo, P.Greninger, S.V.Sharma, J.Settleman, D.A.Compton, and E.Dmitrovsky (2010).
Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe.
  Clin Cancer Res, 16, 109-120.  
20959006 J.B.Stevens, B.Y.Abdallah, S.M.Regan, G.Liu, S.W.Bremer, C.J.Ye, and H.H.Heng (2010).
Comparison of mitotic cell death by chromosome fragmentation to premature chromosome condensation.
  Mol Cytogenet, 3, 20.  
  20054100 J.Holcakova, P.Tomasec, J.J.Bugert, E.C.Wang, G.W.Wilkinson, R.Hrstka, V.Krystof, M.Strnad, and B.Vojtesek (2010).
The inhibitor of cyclin-dependent kinases, olomoucine II, exhibits potent antiviral properties.
  Antivir Chem Chemother, 20, 133-142.  
20889493 M.Morita, K.Hamao, S.Izumi, E.Okumura, K.Tanaka, T.Kishimoto, and H.Hosoya (2010).
Proline-rich domain in dynamin-2 has a low microtubule-binding activity: how is this activity controlled during mitosis in HeLa cells?
  J Biochem, 148, 533-538.  
19174463 A.Grob, P.Roussel, J.E.Wright, B.McStay, D.Hernandez-Verdun, and V.Sirri (2009).
Involvement of SIRT7 in resumption of rDNA transcription at the exit from mitosis.
  J Cell Sci, 122, 489-498.  
19297489 A.J.Kapasi, C.L.Clark, K.Tran, and D.H.Spector (2009).
Recruitment of cdk9 to the immediate-early viral transcriptosomes during human cytomegalovirus infection requires efficient binding to cyclin T1, a threshold level of IE2 86, and active transcription.
  J Virol, 83, 5904-5917.  
19415659 D.Raffa, B.Maggio, S.Cascioferro, M.V.Raimondi, G.Daidone, S.Plescia, D.Schillaci, M.G.Cusimano, L.Titone, C.Colomba, and M.Tolomeo (2009).
N-(indazolyl)benzamido derivatives as CDK1 inhibitors: design, synthesis, biological activity, and molecular docking studies.
  Arch Pharm (Weinheim), 342, 265-273.  
19043750 G.B.Barcellos, R.A.Caceres, and Azevedo (2009).
Structural studies of shikimate dehydrogenase from Bacillus anthracis complexed with cofactor NADP.
  J Mol Model, 15, 147-155.  
19723060 J.Wesierska-Gadek, and V.Krystof (2009).
Selective cyclin-dependent kinase inhibitors discriminating between cell cycle and transcriptional kinases: future reality or utopia?
  Ann N Y Acad Sci, 1171, 228-241.  
19723062 M.Maurer, O.Komina, and J.Wesierska-Gadek (2009).
Roscovitine differentially affects asynchronously growing and synchronized human MCF-7 breast cancer cells.
  Ann N Y Acad Sci, 1171, 250-256.  
19039815 M.Orzáez, A.Gortat, L.Mondragón, O.Bachs, and E.Pérez-Payá (2009).
ATP-noncompetitive inhibitors of CDK-cyclin complexes.
  ChemMedChem, 4, 19-24.  
21581908 M.Rouchal, M.Nečas, Carvalho, and R.Vícha (2009).
  Acta Crystallogr Sect E Struct Rep Online, 65, o298-o299.  
19003963 M.V.Appleyard, M.A.O'Neill, K.E.Murray, F.E.Paulin, S.E.Bray, N.M.Kernohan, D.A.Levison, D.P.Lane, and A.M.Thompson (2009).
Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model.
  Int J Cancer, 124, 465-472.  
19244476 S.B.Ganapathi, M.Kester, and K.S.Elmslie (2009).
State-dependent block of HERG potassium channels by R-roscovitine: implications for cancer therapy.
  Am J Physiol Cell Physiol, 296, C701-C710.  
19723061 S.Wandl, and J.Wesierska-Gadek (2009).
Is olomoucine, a weak CDK2 inhibitor, able to induce apoptosis in cancer cells?
  Ann N Y Acad Sci, 1171, 242-249.  
19619927 W.Wang, B.Bu, M.Xie, M.Zhang, Z.Yu, and D.Tao (2009).
Neural cell cycle dysregulation and central nervous system diseases.
  Prog Neurobiol, 89, 1.  
19028587 X.Huang, P.Finerty, J.R.Walker, C.Butler-Cole, M.Vedadi, M.Schapira, S.A.Parker, B.E.Turk, D.A.Thompson, and S.Dhe-Paganon (2009).
Structural insights into the inhibited states of the Mer receptor tyrosine kinase.
  J Struct Biol, 165, 88-96.
PDB codes: 2p0c 3bpr 3brb
19687009 X.Yang, H.Li, X.S.Liu, A.Deng, and X.Liu (2009).
Cdc2-mediated phosphorylation of CLIP-170 is essential for its inhibition of centrosome reduplication.
  J Biol Chem, 284, 28775-28782.  
17942543 A.J.Kapasi, and D.H.Spector (2008).
Inhibition of the cyclin-dependent kinases at the beginning of human cytomegalovirus infection specifically alters the levels and localization of the RNA polymerase II carboxyl-terminal domain kinases cdk9 and cdk7 at the viral transcriptosome.
  J Virol, 82, 394-407.  
18171934 B.Langley, M.A.D'Annibale, K.Suh, I.Ayoub, A.Tolhurst, B.Bastan, L.Yang, B.Ko, M.Fisher, S.Cho, M.F.Beal, and R.R.Ratan (2008).
Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection.
  J Neurosci, 28, 163-176.  
18855662 C.X.Gong, and K.Iqbal (2008).
Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease.
  Curr Med Chem, 15, 2321-2328.  
17926351 D.Han, B.T.Zhao, Y.Liu, J.J.Li, Y.G.Wu, G.C.Lan, and J.H.Tan (2008).
Interactive effects of low temperature and roscovitine (ROS) on meiotic resumption and developmental potential of goat oocytes.
  Mol Reprod Dev, 75, 838-846.  
19032760 D.R.Caffrey, E.A.Lunney, and D.J.Moshinsky (2008).
Prediction of specificity-determining residues for small-molecule kinase inhibitors.
  BMC Bioinformatics, 9, 491.  
19046382 H.M.Chen, L.Wang, and S.R.D'Mello (2008).
A chemical compound commonly used to inhibit PKR, {8-(imidazol-4-ylmethylene)-6H-azolidino[5,4-g] benzothiazol-7-one}, protects neurons by inhibiting cyclin-dependent kinase.
  Eur J Neurosci, 28, 2003-2016.  
18042686 I.Bártová, J.Koca, and M.Otyepka (2008).
Functional flexibility of human cyclin-dependent kinase-2 and its evolutionary conservation.
  Protein Sci, 17, 22-33.  
19119451 K.C.Shin, C.G.Park, E.S.Hwang, and C.Y.Cha (2008).
Human Cytomegalovirus IE1 Protein Enhances Herpes Simplex Virus Type 1-induced Syncytial Formation in U373MG Cells.
  J Korean Med Sci, 23, 1046-1052.  
17942546 K.Tran, J.A.Mahr, J.Choi, J.G.Teodoro, M.R.Green, and D.H.Spector (2008).
Accumulation of substrates of the anaphase-promoting complex (APC) during human cytomegalovirus infection is associated with the phosphorylation of Cdh1 and the dissociation and relocalization of APC subunits.
  J Virol, 82, 529-537.  
18181150 M.K.Jones, O.R.Padilla, N.A.Webb, and M.Norng (2008).
The anti-apoptosis protein, survivin, mediates gastric epithelial cell cytoprotection against ethanol-induced injury via activation of the p34(cdc2) cyclin-dependent kinase.
  J Cell Physiol, 215, 750-764.  
18490441 M.M.Koseoglu, L.M.Graves, and W.F.Marzluff (2008).
Phosphorylation of threonine 61 by cyclin a/Cdk1 triggers degradation of stem-loop binding protein at the end of S phase.
  Mol Cell Biol, 28, 4469-4479.  
18777593 M.S.Abaza, A.M.Bahman, and R.J.Al-Attiyah (2008).
Roscovitine synergizes with conventional chemo-therapeutic drugs to induce efficient apoptosis of human colorectal cancer cells.
  World J Gastroenterol, 14, 5162-5175.  
18778306 M.Zhang, J.L.Hallows, X.Wang, B.Bu, W.Wang, and I.Vincent (2008).
Mitogen-activated protein kinase activity may not be necessary for the neuropathology of Niemann-Pick type C mice.
  J Neurochem, 107, 814-822.  
18370874 P.C.Wu, M.H.Tai, D.N.Hu, C.H.Lai, Y.H.Chen, Y.C.Wu, C.L.Tsai, S.J.Shin, and H.K.Kuo (2008).
Cyclin-dependent kinase inhibitor roscovitine induces cell cycle arrest and apoptosis in rabbit retinal pigment epithelial cells.
  J Ocul Pharmacol Ther, 24, 25-33.  
18356301 Q.Kan, S.Jinno, H.Yamamoto, K.Kobayashi, and H.Okayama (2008).
ATP-dependent activation of p21WAF1/CIP1-associated Cdk2 by Cdc6.
  Proc Natl Acad Sci U S A, 105, 4757-4762.  
18501396 S.C.McNeely, B.F.Taylor, and J.C.States (2008).
Mitotic arrest-associated apoptosis induced by sodium arsenite in A375 melanoma cells is BUBR1-dependent.
  Toxicol Appl Pharmacol, 231, 61-67.  
17937404 T.O.Fischmann, A.Hruza, J.S.Duca, L.Ramanathan, T.Mayhood, W.T.Windsor, H.V.Le, T.J.Guzi, M.P.Dwyer, K.Paruch, R.J.Doll, E.Lees, D.Parry, W.Seghezzi, and V.Madison (2008).
Structure-guided discovery of cyclin-dependent kinase inhibitors.
  Biopolymers, 89, 372-379.
PDB codes: 2r3f 2r3g 2r3h 2r3i 2r3j 2r3k 2r3l 2r3m 2r3n 2r3o 2r3p 2r3q 2r3r
  18769144 Y.Huang, T.Sen, J.Nagpal, S.Upadhyay, B.Trink, E.Ratovitski, and D.Sidransky (2008).
ATM kinase is a master switch for the Delta Np63 alpha phosphorylation/degradation in human head and neck squamous cell carcinoma cells upon DNA damage.
  Cell Cycle, 7, 2846-2855.  
18221369 Z.Buraei, and K.S.Elmslie (2008).
The separation of antagonist from agonist effects of trisubstituted purines on CaV2.2 (N-type) channels.
  J Neurochem, 105, 1450-1461.  
17846426 A.Errico, V.Costanzo, and T.Hunt (2007).
Tipin is required for stalled replication forks to resume DNA replication after removal of aphidicolin in Xenopus egg extracts.
  Proc Natl Acad Sci U S A, 104, 14929-14934.  
16770643 B.Zhang, V.B.Tan, K.M.Lim, T.E.Tay, and S.Zhuang (2007).
Study of the inhibition of cyclin-dependent kinases with roscovitine and indirubin-3'-oxime from molecular dynamics simulations.
  J Mol Model, 13, 79-89.  
17179992 C.Benson, J.White, J.De Bono, A.O'Donnell, F.Raynaud, C.Cruickshank, H.McGrath, M.Walton, P.Workman, S.Kaye, J.Cassidy, A.Gianella-Borradori, I.Judson, and C.Twelves (2007).
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days.
  Br J Cancer, 96, 29-37.  
17225251 D.Guiffant, D.Tribouillard, F.Gug, H.Galons, L.Meijer, M.Blondel, and S.Bach (2007).
Identification of intracellular targets of small molecular weight chemical compounds using affinity chromatography.
  Biotechnol J, 2, 68-75.  
17318617 H.Song, M.Vita, H.Sallam, R.Tehranchi, C.Nilsson, A.Sidén, and Z.Hassan (2007).
Effect of the Cdk-inhibitor roscovitine on mouse hematopoietic progenitors in vivo and in vitro.
  Cancer Chemother Pharmacol, 60, 841-849.  
17085505 J.H.Alzate-Morales, R.Contreras, A.Soriano, I.Tuñon, and E.Silla (2007).
A computational study of the protein-ligand interactions in CDK2 inhibitors: using quantum mechanics/molecular mechanics interaction energy as a predictor of the biological activity.
  Biophys J, 92, 430-439.  
17975794 J.Wesierska-Gadek, M.Gueorguieva, M.P.Kramer, C.Ranftler, B.Sarg, and H.Lindner (2007).
A new, unexpected action of olomoucine, a CDK inhibitor, on normal human cells: up-regulation of CLIMP-63, a cytoskeleton-linking membrane protein.
  J Cell Biochem, 102, 1405-1419.  
17203463 J.Wesierska-Gadek, M.L.Schmitz, and C.Ranftler (2007).
Roscovitine-activated HIP2 kinase induces phosphorylation of wt p53 at Ser-46 in human MCF-7 breast cancer cells.
  J Cell Biochem, 100, 865-874.  
17415788 J.Wesierska-Gadek, M.Maurer, and G.Schmid (2007).
Inhibition of farnesyl protein transferase sensitizes human MCF-7 breast cancer cells to roscovitine-mediated cell cycle arrest.
  J Cell Biochem, 102, 736-747.  
17339323 L.Spíchal, V.Krystof, M.Paprskárová, R.Lenobel, J.Styskala, P.Binarová, V.Cenklová, L.De Veylder, D.Inzé, G.Kontopidis, P.M.Fischer, T.Schmülling, and M.Strnad (2007).
Classical anticytokinins do not interact with cytokinin receptors but inhibit cyclin-dependent kinases.
  J Biol Chem, 282, 14356-14363.  
17541419 M.P.Mazanetz, and P.M.Fischer (2007).
Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases.
  Nat Rev Drug Discov, 6, 464-479.  
16951685 A.G.Rossi, D.A.Sawatzky, A.Walker, C.Ward, T.A.Sheldrake, N.A.Riley, A.Caldicott, M.Martinez-Losa, T.R.Walker, R.Duffin, M.Gray, E.Crescenzi, M.C.Martin, H.J.Brady, J.S.Savill, I.Dransfield, and C.Haslett (2006).
Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis.
  Nat Med, 12, 1056-1064.  
16327781 A.Jazayeri, J.Falck, C.Lukas, J.Bartek, G.C.Smith, J.Lukas, and S.P.Jackson (2006).
ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks.
  Nat Cell Biol, 8, 37-45.  
16158051 A.Krystyniak, C.Garcia-Echeverria, C.Prigent, and S.Ferrari (2006).
Inhibition of Aurora A in response to DNA damage.
  Oncogene, 25, 338-348.  
17054019 B.Zhang, V.B.Tan, K.M.Lim, and T.E.Tay (2006).
Molecular dynamics simulations on the inhibition of cyclin-dependent kinases 2 and 5 in the presence of activators.
  J Comput Aided Mol Des, 20, 395-404.  
16492148 D.Dalgarno, T.Stehle, S.Narula, P.Schelling, M.R.van Schravendijk, S.Adams, L.Andrade, J.Keats, M.Ram, L.Jin, T.Grossman, I.MacNeil, C.Metcalf, W.Shakespeare, Y.Wang, T.Keenan, R.Sundaramoorthi, R.Bohacek, M.Weigele, and T.Sawyer (2006).
Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
  Chem Biol Drug Des, 67, 46-57.
PDB codes: 2bdf 2bdj
16584130 J.Sridhar, N.Akula, and N.Pattabiraman (2006).
Selectivity and potency of cyclin-dependent kinase inhibitors.
  AAPS J, 8, E204-E221.  
16741967 J.Wesierska-Gadek, T.Schreiner, M.Gueorguieva, and C.Ranftler (2006).
Phenol red reduces ROSC mediated cell cycle arrest and apoptosis in human MCF-7 cells.
  J Cell Biochem, 98, 1367-1379.  
16892371 M.D.Kelly, and R.L.Mancera (2006).
Comparative analysis of the surface interaction properties of the binding sites of CDK2, CDK4, and ERK2.
  ChemMedChem, 1, 366-375.  
16407256 M.Otyepka, I.Bártová, Z.Kríz, and J.Koca (2006).
Different mechanisms of CDK5 and CDK2 activation as revealed by CDK5/p25 and CDK2/cyclin A dynamics.
  J Biol Chem, 281, 7271-7281.  
16575928 P.Dobes, M.Otyepka, M.Strnad, and P.Hobza (2006).
Interaction energies for the purine inhibitor roscovitine with cyclin-dependent kinase 2: correlated ab initio quantum-chemical, DFT and empirical calculations.
  Chemistry, 12, 4297-4304.  
16321160 C.Doucet, G.J.Gutierrez, C.Lindon, T.Lorca, G.Lledo, C.Pinset, and O.Coux (2005).
Multiple phosphorylation events control mitotic degradation of the muscle transcription factor Myf5.
  BMC Biochem, 6, 27.  
15778585 D.Autret, A.Bitar, L.Ferrer, A.Lisbona, and M.Bardiès (2005).
Monte Carlo modeling of gamma cameras for I-131 imaging in targeted radiotherapy.
  Cancer Biother Radiopharm, 20, 77-84.  
16262700 D.Stabenow, H.Probst, and M.van Betteraey-Nikoleit (2005).
Cdk2 activity is dispensable for triggering replicon initiation after transient hypoxia in T24 cells.
  FEBS J, 272, 5623-5634.  
16075305 K.A.Rossi, J.A.Markwalder, S.P.Seitz, C.H.Chang, S.Cox, M.D.Boisclair, L.Brizuela, S.L.Brenner, and P.F.Stouten (2005).
Understanding and modulating cyclin-dependent kinase inhibitor specificity: molecular modeling and biochemical evaluation of pyrazolopyrimidinones as CDK2/cyclin A and CDK4/cyclin D1 inhibitors.
  J Comput Aided Mol Des, 19, 111-122.  
16096806 K.K.Manhani, H.A.Arcuri, N.J.da Silveira, H.B.Uchôa, Azevedo, and F.Canduri (2005).
Molecular models of protein kinase 6 from Plasmodium falciparum.
  J Mol Model, 12, 42-48.  
15985434 L.Tang, M.H.Li, P.Cao, F.Wang, W.R.Chang, S.Bach, J.Reinhardt, Y.Ferandin, H.Galons, Y.Wan, N.Gray, L.Meijer, T.Jiang, and D.C.Liang (2005).
Crystal structure of pyridoxal kinase in complex with roscovitine and derivatives.
  J Biol Chem, 280, 31220-31229.
PDB codes: 1ygj 1ygk 1yhj
16227297 M.P.Windisch, M.Frese, A.Kaul, M.Trippler, V.Lohmann, and R.Bartenschlager (2005).
Dissecting the interferon-induced inhibition of hepatitis C virus replication by using a novel host cell line.
  J Virol, 79, 13778-13793.  
15759144 N.J.Silveira, H.B.Uchôa, J.H.Pereira, F.Canduri, L.A.Basso, M.S.Palma, D.S.Santos, and Azevedo (2005).
Molecular models of protein targets from Mycobacterium tuberculosis.
  J Mol Model, 11, 160-166.  
15663787 N.J.da Silveira, H.A.Arcuri, C.E.Bonalumi, Souza, I.M.Mello, P.Rahal, J.R.Pinho, and Azevedo (2005).
Molecular models of NS3 protease variants of the Hepatitis C virus.
  BMC Struct Biol, 5, 1.  
16314496 P.K.Pandey, T.S.Udayakumar, X.Lin, D.Sharma, P.S.Shapiro, and J.D.Fondell (2005).
Activation of TRAP/mediator subunit TRAP220/Med1 is regulated by mitogen-activated protein kinase-dependent phosphorylation.
  Mol Cell Biol, 25, 10695-10710.  
15975926 S.Bach, M.Knockaert, J.Reinhardt, O.Lozach, S.Schmitt, B.Baratte, M.Koken, S.P.Coburn, L.Tang, T.Jiang, D.C.Liang, H.Galons, J.F.Dierick, L.A.Pinna, F.Meggio, F.Totzke, C.Schächtele, A.S.Lerman, A.Carnero, Y.Wan, N.Gray, and L.Meijer (2005).
Roscovitine targets, protein kinases and pyridoxal kinase.
  J Biol Chem, 280, 31208-31219.  
16306619 S.Tamrakar, A.J.Kapasi, and D.H.Spector (2005).
Human cytomegalovirus infection induces specific hyperphosphorylation of the carboxyl-terminal domain of the large subunit of RNA polymerase II that is associated with changes in the abundance, activity, and localization of cdk9 and cdk7.
  J Virol, 79, 15477-15493.  
15818598 X.Li, K.Tanaka, F.Nakatani, T.Matsunobu, R.Sakimura, M.Hanada, T.Okada, T.Nakamura, and Y.Iwamoto (2005).
Transactivation of cyclin E gene by EWS-Fli1 and antitumor effects of cyclin dependent kinase inhibitor on Ewing's family tumor cells.
  Int J Cancer, 116, 385-394.  
15153188 E.Blagoeva, P.I.Dobrev, J.Malbeck, V.Motyka, M.Strnad, J.Hanus, and R.Vanková (2004).
Cytokinin N-glucosylation inhibitors suppress deactivation of exogenous cytokinins in radish, but their effect on active endogenous cytokinins is counteracted by other regulatory mechanisms.
  Physiol Plant, 121, 215-222.  
15278910 E.Gomez, A.Rodríguez, F.Goyache, C.Díez, L.José Royo, P.N.Moreira, J.Néstor Caamaño, E.Morán, and A.Gutiérrez-Adán (2004).
Retinoid-dependent mRNA expression and poly-(A) contents in bovine oocytes meiotically arrested and/or matured in vitro.
  Mol Reprod Dev, 69, 101-108.  
15123283 F.Becker, K.Murthi, C.Smith, J.Come, N.Costa-Roldán, C.Kaufmann, U.Hanke, C.Degenhart, S.Baumann, W.Wallner, A.Huber, S.Dedier, S.Dill, D.Kinsman, M.Hediger, N.Bockovich, S.Meier-Ewert, A.F.Kluge, and N.Kley (2004).
A three-hybrid approach to scanning the proteome for targets of small molecule kinase inhibitors.
  Chem Biol, 11, 211-223.  
15502309 M.V.Dias, F.Ely, F.Canduri, J.H.Pereira, J.Frazzon, L.A.Basso, M.S.Palma, Azevedo, and D.S.Santos (2004).
Crystallization and preliminary X-ray crystallographic analysis of chorismate synthase from Mycobacterium tuberculosis.
  Acta Crystallogr D Biol Crystallogr, 60, 2003-2005.  
  15331409 M.Zhang, J.Li, P.Chakrabarty, B.Bu, and I.Vincent (2004).
Cyclin-dependent kinase inhibitors attenuate protein hyperphosphorylation, cytoskeletal lesion formation, and motor defects in Niemann-Pick Type C mice.
  Am J Pathol, 165, 843-853.  
15452241 V.Sanchez, A.K.McElroy, J.Yen, S.Tamrakar, C.L.Clark, R.A.Schwartz, and D.H.Spector (2004).
Cyclin-dependent kinase activity is required at early times for accurate processing and accumulation of the human cytomegalovirus UL122-123 and UL37 immediate-early transcripts and at later times for virus production.
  J Virol, 78, 11219-11232.  
15564503 W.Deng, B.Y.Lin, G.Jin, C.G.Wheeler, T.Ma, J.W.Harper, T.R.Broker, and L.T.Chow (2004).
Cyclin/CDK regulates the nucleocytoplasmic localization of the human papillomavirus E1 DNA helicase.
  J Virol, 78, 13954-13965.  
14743393 Y.C.Cho, and C.R.Jefcoate (2004).
PPARgamma1 synthesis and adipogenesis in C3H10T1/2 cells depends on S-phase progression, but does not require mitotic clonal expansion.
  J Cell Biochem, 91, 336-353.  
15123286 Y.Wan, W.Hur, C.Y.Cho, Y.Liu, F.J.Adrian, O.Lozach, S.Bach, T.Mayer, D.Fabbro, L.Meijer, and N.S.Gray (2004).
Synthesis and target identification of hymenialdisine analogs.
  Chem Biol, 11, 247-259.  
15048820 Z.Kríz, M.Otyepka, I.Bártová, and J.Koca (2004).
Analysis of CDK2 active-site hydration: a method to design new inhibitors.
  Proteins, 55, 258-274.  
12766773 C.Wong, and T.Stearns (2003).
Centrosome number is controlled by a centrosome-intrinsic block to reduplication.
  Nat Cell Biol, 5, 539-544.  
12589660 J.C.Ju, C.Tsay, and C.W.Ruan (2003).
Alterations and reversibility in the chromatin, cytoskeleton and development of pig oocytes treated with roscovitine.
  Mol Reprod Dev, 64, 482-491.  
12845642 J.Wojciechowski, M.Horky, M.Gueorguieva, and J.Wesierska-Gadek (2003).
Rapid onset of nucleolar disintegration preceding cell cycle arrest in roscovitine-induced apoptosis of human MCF-7 breast cancer cells.
  Int J Cancer, 106, 486-495.  
12857729 J.Yun, H.D.Chae, T.S.Choi, E.H.Kim, Y.J.Bang, J.Chung, K.S.Choi, R.Mantovani, and D.Y.Shin (2003).
Cdk2-dependent phosphorylation of the NF-Y transcription factor and its involvement in the p53-p21 signaling pathway.
  J Biol Chem, 278, 36966-36972.  
12799469 M.Yamaguchi, H.Kato, S.Yoshida, S.Yamamura, H.Uchimiya, and M.Umeda (2003).
Control of in vitro organogenesis by cyclin-dependent kinase activities in plants.
  Proc Natl Acad Sci U S A, 100, 8019-8023.  
12556199 N.C.Waters, and J.A.Geyer (2003).
Cyclin-dependent protein kinases as therapeutic drug targets for antimalarial drug development.
  Expert Opin Ther Targets, 7, 7.  
12734188 R.P.St Onge, B.D.Besley, J.L.Pelley, and S.Davey (2003).
A role for the phosphorylation of hRad9 in checkpoint signaling.
  J Biol Chem, 278, 26620-26628.  
12719431 S.A.Didichenko, C.M.Fragoso, and M.Thelen (2003).
Mitotic and stress-induced phosphorylation of HsPI3K-C2alpha targets the protein for degradation.
  J Biol Chem, 278, 26055-26064.  
12654284 S.Grant, and J.D.Roberts (2003).
The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy.
  Drug Resist Updat, 6, 15-26.  
12371965 B.Liu, and P.A.Preisig (2002).
Compensatory renal hypertrophy is mediated by a cell cycle-dependent mechanism.
  Kidney Int, 62, 1650-1658.  
12191602 D.Fabbro, S.Ruetz, E.Buchdunger, S.W.Cowan-Jacob, G.Fendrich, J.Liebetanz, J.Mestan, T.O'Reilly, P.Traxler, B.Chaudhuri, H.Fretz, J.Zimmermann, T.Meyer, G.Caravatti, P.Furet, and P.W.Manley (2002).
Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.
  Pharmacol Ther, 93, 79-98.  
12121920 D.L.Evers, J.M.Breitenbach, K.Z.Borysko, L.B.Townsend, and J.C.Drach (2002).
Inhibition of cyclin-dependent kinase 1 by purines and pyrrolo[2,3-d]pyrimidines does not correlate with antiviral activity.
  Antimicrob Agents Chemother, 46, 2470-2476.  
12006500 I.Frouin, A.Montecucco, G.Biamonti, U.Hübscher, S.Spadari, and G.Maga (2002).
Cell cycle-dependent dynamic association of cyclin/Cdk complexes with human DNA replication proteins.
  EMBO J, 21, 2485-2495.  
11807175 I.R.Hardcastle, B.T.Golding, and R.J.Griffin (2002).
Designing inhibitors of cyclin-dependent kinases.
  Annu Rev Pharmacol Toxicol, 42, 325-348.  
12097601 L.M.Schang, A.Bantly, M.Knockaert, F.Shaheen, L.Meijer, M.H.Malim, N.S.Gray, and P.A.Schaffer (2002).
Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins.
  J Virol, 76, 7874-7882.  
12237154 M.Knockaert, P.Greengard, and L.Meijer (2002).
Pharmacological inhibitors of cyclin-dependent kinases.
  Trends Pharmacol Sci, 23, 417-425.  
12120282 P.Cohen (2002).
Protein kinases--the major drug targets of the twenty-first century?
  Nat Rev Drug Discov, 1, 309-315.  
11741924 S.Dutertre, R.Sekhri, L.A.Tintignac, R.Onclercq-Delic, B.Chatton, C.Jaulin, and M.Amor-Guéret (2002).
Dephosphorylation and subcellular compartment change of the mitotic Bloom's syndrome DNA helicase in response to ionizing radiation.
  J Biol Chem, 277, 6280-6286.  
12432547 S.J.McClue, D.Blake, R.Clarke, A.Cowan, L.Cummings, P.M.Fischer, M.MacKenzie, J.Melville, K.Stewart, S.Wang, N.Zhelev, D.Zheleva, and D.P.Lane (2002).
In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine).
  Int J Cancer, 102, 463-468.  
12191605 T.G.Davies, D.J.Pratt, J.A.Endicott, L.N.Johnson, and M.E.Noble (2002).
Structure-based design of cyclin-dependent kinase inhibitors.
  Pharmacol Ther, 93, 125-133.  
12244298 T.G.Davies, J.Bentley, C.E.Arris, F.T.Boyle, N.J.Curtin, J.A.Endicott, A.E.Gibson, B.T.Golding, R.J.Griffin, I.R.Hardcastle, P.Jewsbury, L.N.Johnson, V.Mesguiche, D.R.Newell, M.E.Noble, J.A.Tucker, L.Wang, and H.J.Whitfield (2002).
Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor.
  Nat Struct Biol, 9, 745-749.
PDB codes: 1h1p 1h1q 1h1r 1h1s
11901165 V.Sirri, D.Hernandez-Verdun, and P.Roussel (2002).
Cyclin-dependent kinases govern formation and maintenance of the nucleolus.
  J Cell Biol, 156, 969-981.  
11679720 F.Canduri, L.G.Teodoro, V.Fadel, C.C.Lorenzi, V.Hial, R.A.Gomes, J.R.Neto, and Azevedo (2001).
Structure of human uropepsin at 2.45 A resolution.
  Acta Crystallogr D Biol Crystallogr, 57, 1560-1570.
PDB code: 1flh
11292825 G.Hu, G.F.Jang, C.W.Cowan, T.G.Wensel, and K.Palczewski (2001).
Phosphorylation of RGS9-1 by an endogenous protein kinase in rod outer segments.
  J Biol Chem, 276, 22287-22295.  
11342062 P.Delatorre, J.R.Olivieri, J.Ruggiero Neto, C.C.Lorenzi, F.Canduri, V.Fadel, K.Konno, M.S.Palma, T.Yamane, and Azevedo (2001).
Preliminary cryocrystallography analysis of an eumenine mastoparan toxin isolated from the venom of the wasp Anterhynchium flavomarginatum micado.
  Biochim Biophys Acta, 1545, 372-376.  
11607930 P.L.Toogood (2001).
Cyclin-dependent kinase inhibitors for treating cancer.
  Med Res Rev, 21, 487-498.  
11604527 R.Battistutta, E.De Moliner, S.Sarno, G.Zanotti, and L.A.Pinna (2001).
Structural features underlying selective inhibition of protein kinase CK2 by ATP site-directed tetrabromo-2-benzotriazole.
  Protein Sci, 10, 2200-2206.
PDB codes: 1j91 1jam
11550269 R.Marchal, M.Tomanek, M.Terqui, and P.Mermillod (2001).
Effects of cell cycle dependent kinases inhibitor on nuclear and cytoplasmic maturation of porcine oocytes.
  Mol Reprod Dev, 60, 65-73.  
12030783 S.Wadler (2001).
Perspectives for cancer therapies with cdk2 inhibitors.
  Drug Resist Updat, 4, 347-367.  
10931861 A.B.Dirac-Svejstrup, J.Shorter, M.G.Waters, and G.Warren (2000).
Phosphorylation of the vesicle-tethering protein p115 by a casein kinase II-like enzyme is required for Golgi reassembly from isolated mitotic fragments.
  J Cell Biol, 150, 475-488.  
10608920 C.García-Echeverría, P.Traxler, and D.B.Evans (2000).
ATP site-directed competitive and irreversible inhibitors of protein kinases.
  Med Res Rev, 20, 28-57.  
10858286 D.I.Zheleva, N.Z.Zhelev, P.M.Fischer, S.V.Duff, E.Warbrick, D.G.Blake, and D.P.Lane (2000).
A quantitative study of the in vitro binding of the C-terminal domain of p21 to PCNA: affinity, stoichiometry, and thermodynamics.
  Biochemistry, 39, 7388-7397.  
11271495 H.Kovárová, M.Hajdúch, G.Korínková, P.Halada, S.Krupicková, A.Gouldsworthy, N.Zhelev, and M.Strnad (2000).
Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyclin-dependent kinase inhibitor, bohemine.
  Electrophoresis, 21, 3757-3764.  
10666240 L.M.Schang, A.Rosenberg, and P.A.Schaffer (2000).
Roscovitine, a specific inhibitor of cellular cyclin-dependent kinases, inhibits herpes simplex virus DNA synthesis in the presence of viral early proteins.
  J Virol, 74, 2107-2120.  
10662688 L.Meijer, A.M.Thunnissen, A.W.White, M.Garnier, M.Nikolic, L.H.Tsai, J.Walter, K.E.Cleverley, P.C.Salinas, Y.Z.Wu, J.Biernat, E.M.Mandelkow, S.H.Kim, and G.R.Pettit (2000).
Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent.
  Chem Biol, 7, 51-63.
PDB code: 1dm2
11498372 L.Meijer (2000).
Cyclin-dependent kinases inhibitors as potential anticancer, antineurodegenerative, antiviral and antiparasitic agents.
  Drug Resist Updat, 3, 83-88.  
11092946 R.T.Honda, P.Delatorre, V.Fadel, F.Canduri, M.Dellamano, Azevedo, and G.O.Bonilla-Rodriguez (2000).
Crystallization, preliminary X-ray analysis and molecular-replacement solution of the carboxy form of haemoglobin I from the fish Brycon cephalus.
  Acta Crystallogr D Biol Crystallogr, 56, 1685-1687.  
10788489 T.Krude (2000).
Initiation of human DNA replication in vitro using nuclei from cells arrested at an initiation-competent state.
  J Biol Chem, 275, 13699-13707.  
10648559 V.Sirri, P.Roussel, and D.Hernandez-Verdun (2000).
In vivo release of mitotic silencing of ribosomal gene transcription does not give rise to precursor ribosomal RNA processing.
  J Cell Biol, 148, 259-270.  
10207019 A.Borgne, A.C.Ostvold, S.Flament, and L.Meijer (1999).
Intra-M phase-promoting factor phosphorylation of cyclin B at the prophase/metaphase transition.
  J Biol Chem, 274, 11977-11986.  
10531493 F.A.Seixas, Azevedo, and M.F.Colombo (1999).
Crystallization and x-ray diffraction data analysis of human deoxyhaemoglobin A(0) fully stripped of any anions.
  Acta Crystallogr D Biol Crystallogr, 55, 1914-1916.  
10454194 J.M.Sowadski, L.F.Epstein, L.Lankiewicz, and R.Karlsson (1999).
Conformational diversity of catalytic cores of protein kinases.
  Pharmacol Ther, 82, 157-164.  
10542199 K.S.Choi, Y.W.Eom, Y.Kang, M.J.Ha, H.Rhee, J.W.Yoon, and S.J.Kim (1999).
Cdc2 and Cdk2 kinase activated by transforming growth factor-beta1 trigger apoptosis through the phosphorylation of retinoblastoma protein in FaO hepatoma cells.
  J Biol Chem, 274, 31775-31783.  
  9971799 L.M.Schang, A.Rosenberg, and P.A.Schaffer (1999).
Transcription of herpes simplex virus immediate-early and early genes is inhibited by roscovitine, an inhibitor specific for cellular cyclin-dependent kinases.
  J Virol, 73, 2161-2172.  
10072351 M.D.Garrett, and A.Fattaey (1999).
CDK inhibition and cancer therapy.
  Curr Opin Genet Dev, 9, 104-111.  
10454204 M.E.Noble, and J.A.Endicott (1999).
Chemical inhibitors of cyclin-dependent kinases: insights into design from X-ray crystallographic studies.
  Pharmacol Ther, 82, 269-278.  
  9882337 M.Ye, K.M.Duus, J.Peng, D.H.Price, and C.Grose (1999).
Varicella-zoster virus Fc receptor component gI is phosphorylated on its endodomain by a cyclin-dependent kinase.
  J Virol, 73, 1320-1330.  
10029530 N.Narayana, T.C.Diller, K.Koide, M.E.Bunnage, K.C.Nicolaou, L.L.Brunton, N.H.Xuong, L.F.Ten Eyck, and S.S.Taylor (1999).
Crystal structure of the potent natural product inhibitor balanol in complex with the catalytic subunit of cAMP-dependent protein kinase.
  Biochemistry, 38, 2367-2376.
PDB code: 1bx6
10419844 P.Cohen (1999).
The development and therapeutic potential of protein kinase inhibitors.
  Curr Opin Chem Biol, 3, 459-465.  
9727024 G.N.Patrick, P.Zhou, Y.T.Kwon, P.M.Howley, and L.H.Tsai (1998).
p35, the neuronal-specific activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the ubiquitin-proteasome pathway.
  J Biol Chem, 273, 24057-24064.  
15992004 K.R.Webster (1998).
The therapeutic potential of targeting the cell cycle.
  Expert Opin Investig Drugs, 7, 865-887.  
  9621021 L.M.Schang, J.Phillips, and P.A.Schaffer (1998).
Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription.
  J Virol, 72, 5626-5637.  
  9671459 O.W.Prall, E.M.Rogan, E.A.Musgrove, C.K.Watts, and R.L.Sutherland (1998).
c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry.
  Mol Cell Biol, 18, 4499-4508.  
9753691 Z.Wang, B.J.Canagarajah, J.C.Boehm, S.Kassisà, M.H.Cobb, P.R.Young, S.Abdel-Meguid, J.L.Adams, and E.J.Goldsmith (1998).
Structural basis of inhibitor selectivity in MAP kinases.
  Structure, 6, 1117-1128.
PDB codes: 1a9u 1bl6 1bl7 1bmk 3erk 4erk
9334743 A.M.Lawrie, M.E.Noble, P.Tunnah, N.R.Brown, L.N.Johnson, and J.A.Endicott (1997).
Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2.
  Nat Struct Biol, 4, 796-801.
PDB code: 1aq1
9366565 J.W.Pippin, Q.Qu, L.Meijer, and S.J.Shankland (1997).
Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist.
  J Clin Invest, 100, 2512-2520.  
9030781 L.Meijer, A.Borgne, O.Mulner, J.P.Chong, J.J.Blow, N.Inagaki, M.Inagaki, J.G.Delcros, and J.P.Moulinoux (1997).
Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
  Eur J Biochem, 243, 527-536.  
The most recent references are shown first. Citation data come partly from CiteXplore and partly from an automated harvesting procedure. Note that this is likely to be only a partial list as not all journals are covered by either method. However, we are continually building up the citation data so more and more references will be included with time. Where a reference describes a PDB structure, the PDB codes are shown on the right.